NGNE – neurogene inc. (US:NASDAQ)
Stock Stats
News
Neurogene Inc. (NASDAQ: NGNE) had its price target lowered by analysts at HC Wainwright from $55.00 to $51.00. They now have a "buy" rating on the stock.
Neurogene Reports First Quarter 2024 Financial Results and Highlights Recent Updates
Neurogene Presents Favorable Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome during ASGCT Annual Meeting [Yahoo! Finance]
Neurogene Presents Favorable Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome during ASGCT Annual Meeting
Neurogene Inc. (NASDAQ: NGNE) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $55.00 price target on the stock.
Form 10-Q Neurogene Inc. For: Mar 31
Form 8-K Neurogene Inc. For: May 10
Form 8-K Neurogene Inc. For: May 07
Form DEFA14A Neurogene Inc.
Form ARS Neurogene Inc. For: Dec 31
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.